Log In
Print this Print this

Human mAb against interleukin-13 (IL-13)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionHuman mAb against interleukin-13 (IL-13)
Molecular Target Interleukin-13 (IL-13)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationEosinophilic esophagitis
Indication DetailsTreat eosinophilic esophagitis
Regulatory Designation U.S. - Orphan Drug (Treat eosinophilic esophagitis);
EU - Orphan Drug (Treat eosinophilic esophagitis)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today